Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9686
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOlver, James Sen
dc.contributor.authorBurrows, Graham Den
dc.contributor.authorNorman, Trevor Ren
dc.date.accessioned2015-05-15T22:52:19Z
dc.date.available2015-05-15T22:52:19Z
dc.date.issued2004-01-01en
dc.identifier.citationHuman Psychopharmacology; 19(1): 9-16en
dc.identifier.govdoc14716706en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9686en
dc.description.abstractVenlafaxine is the first of a group of antidepressants that show dual reuptake inhibition of serotonin and noradrenaline (SNRIs). Originally marketed in an immediate release (IR) formulation a microencapsulated, extended release (XR) formulation is now available. Significant differences exist between these two formulations with respect to pharmacokinetic parameters which have an impact on clinical use. The XR has lower maximum plasma concentrations (Cmax) and achieves these at a later time (higher Tmax). The longer apparent elimination half-life of the drug after single XR doses suggests that it is suitable for once daily dosing compared with the twice daily dosing regimen required by the IR formulation. With respect to antidepressant efficacy the XR formulation is equivalent to other marketed antidepressants and to the IR formulation. Consistent with its pharmacokinetic properties the use of the XR formulation is associated with less nausea and dizziness at the initiation of therapy. While in clinical usage XR might be expected to increase compliance with medication and to reduce discontinuation syndromes there are few comparative studies for which this has been evaluated. The XR formulation of venlafaxine is no worse than the IR form with respect to tolerability and offers some benefits to patients in terms of ease of use. On the other hand there does not appear to be any increase in the efficacy of the active agent.en
dc.language.isoenen
dc.subject.otherAntidepressive Agents, Second-Generation.administration & dosage.pharmacokinetics.therapeutic useen
dc.subject.otherClinical Trials as Topicen
dc.subject.otherCyclohexanols.administration & dosage.pharmacokinetics.therapeutic useen
dc.subject.otherDelayed-Action Preparationsen
dc.subject.otherDepressive Disorder.drug therapyen
dc.subject.otherHumansen
dc.titleThe treatment of depression with different formulations of venlafaxine: a comparative analysis.en
dc.typeJournal Articleen
dc.identifier.journaltitleHuman psychopharmacologyen
dc.identifier.affiliationDepartment of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1002/hup.551en
dc.description.pages9-16en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/14716706en
dc.type.austinJournal Articleen
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
crisitem.author.deptPsychiatry (University of Melbourne)-
crisitem.author.deptPsychiatry (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Jan 29, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.